Key result
Avatrombopag is an effective oral thrombopoietin receptor agonist for immune thrombocytopenia that does not require dietary restrictions, though it may carry a risk of thromboembolism.
Why the study?
Existing thrombopoietin receptor agonists for immune thrombocytopenia have clinical limitations, including dietary and drug interaction restrictions with eltrombopag and the requirement for weekly clinic visits for romiplostim subcutaneous injections.
Is avatrombopag effective and safe for the treatment of immune thrombocytopenia?
Is avatrombopag effective and safe for the treatment of immune thrombocytopenia?
Avatrombopag offers a convenient, food-independent oral treatment option for ITP with high efficacy, though thromboembolic risk requires monitoring.
Answers are grounded in this paper and cite their sources.
Avatrombopag may offer convenient ITP therapy without food restrictions; leaves open prospective confirmation of thromboembolic safety.
免疫性血小板減少症（特発性血小板減少性紫斑病，immune thrombocytopenia, idiopathic thrombocytopenic purpura: ITP）におけるトロンボポエチン（thrombopoietin: TPO）受容体作動薬の有効性および安全性は，先行するエルトロンボパグ（eltrombopag: EPAG）およびロミプロスチム（romiplostim: ROMI）により示されてきた．しかしEPAGは食事や薬剤の影響を受けやすく内服時間や併用薬の制約が大きいこと，またROMIは皮下注製剤であり，かつ自己注射は認められておらず，週1回の来院が必要であることが大きな制約となっていた．新しいTPO受容体作動薬であるアバトロンボパグはEPAGと異なり，食事や薬剤の強い影響を受けない内服薬である．その有効性はEPAGやROMIと同等であり，またこれら2剤の無効例においても有効性が報告されている．血栓塞栓症の頻度がやや高い可能性があることに対し注意が必要であるが，有効性の高さと使いやすさから早期の承認が待たれる薬剤である．
No takes yet. Share an insight, caveat, or question.
Hirokazu Kashiwagi (2024) conducted a review in Immune thrombocytopenia (ITP). Avatrombopag vs. Placebo, Eltrombopag, Romiplostim was evaluated on Number of weeks with platelet response (> 50,000/μL) in the highlighted Phase 3 RCT (p=<0.0001). Avatrombopag is an effective oral thrombopoietin receptor agonist for immune thrombocytopenia that does not require dietary restrictions, though it may carry a risk of thromboembolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: